Examination of effectiveness of combination therapy of periodontal tissue regeneration drug, Regroth, and carbonate apatite, Cytrans Granules, for periodontal tissue regenaration

Examination of effectiveness of combination therapy of periodontal tissue regeneration drug, Regroth, and carbonate apatite, Cytrans Granules, for periodontal tissue regenaration - Study on combination therapy of Regroth and Cytrans Granules for periodontal tissue regeneration

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000037940

Enrollment

Registered

2020-01-01

Start date

2019-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal Disease

Interventions

Combination therapy of Regroth and Cytrans Granules at periodontal surgical treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Periodontal pocket depth of 4 mm or more, and vertical bone defect of 3 mm or more

Exclusion criteria

Exclusion criteria: Patients with severe systemic disease Patients who may be pregnant or pregnant Patients with mental illness Patients with hypersensitivity to "Regroth" or "Cytrans Granules" Patients with malignant tumor in oral cavity or patients with its history Case of predicted not to able to complete closure of wound surface when filling with Cytrans Granules Tooth for severe periodontal disease and tooth extraction adapted tooth

Design outcomes

Primary

Measure	Time frame
Increase in new alveolar bone at 9 months after periodontal surgery	—

Countries

Japan

Contacts

Public ContactHiromichi Yumoto

Tokushima University Graduate School Department of Periodontology and Endodontology

yumoto@tokushima-u.ac.jp0886337343

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026